Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY6FUD)

Drug Name
(Hydroxyethyloxy)Tri(Ethyloxy)Octane Drug Info
Synonyms
19327-39-0; 3,6,9,12-tetraoxaicosan-1-ol; 3,6,9,12-Tetraoxaeicosan-1-ol; TETRAETHYLENE GLYCOL MONOOCTYL ETHER; (Hydroxyethyloxy)tri(Ethyloxy)octane; Tetraethylene glycol monoctyl ether; C8E4; FEOZZFHAVXYAMB-UHFFFAOYSA-N; C8E; Octyltetraglycol; Octyltetraethyleneoxide; AC1L1KAZ; AC1Q58VY; SCHEMBL185557; Octyl tetraethylene glycol ether; DTXSID3066479; CHEBI:41323; CTK0H5811; Tetraethylene glycol, octyl ether; tetraethyleneglycol monooctyl ether; MolPort-003-939-472; MFCD00043033; ZINC14881140; AKOS027320403; DB04233; KS-00000Y06
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5414
ChEBI ID
CHEBI:41323
CAS Number
CAS 19327-39-0
TTD Drug ID
DMY6FUD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Rhodopsin (RHO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [1]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [1]
L-serine-O-phosphate DMTJ1NH Discovery agent N.A. Investigative [1]
Phosphonothreonine DMTFHPI Discovery agent N.A. Investigative [1]
Beta-D-Mannose DMHIG9K Discovery agent N.A. Investigative [1]
Hexadecanoic acid DMWUXDZ Discovery agent N.A. Investigative [1]
NSC-88915 DM9WIHJ Solid tumour/cancer 2A00-2F9Z Investigative [2]
Lauryl Dimethylamine-N-Oxide DM3W2OE Discovery agent N.A. Investigative [1]
B-2-Octylglucoside DMEGX8H Discovery agent N.A. Investigative [1]
B-Nonylglucoside DM48VJR Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Pancreatic triacylglycerol lipase (PNLIP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Orlistat DMRJSP8 Obesity 5B81 Approved [4]
Dalbavancin DMGMNH3 Bacterial infection 1A00-1C4Z Approved [5]
Pancrecarb DMOML9Q Pancreatic malfunction DC30-DC3Z NDA filed [6]
Liprotamase DMNF4UH Cystic fibrosis CA25 Phase 3 [7]
MS-1819 DM35YFC Exocrine pancreatic insufficiency DC35.1 Phase 1/2 [8]
AZM-131 DMLCSRF Obesity 5B81 Terminated [9]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [1]
B-Nonylglucoside DM48VJR Discovery agent N.A. Investigative [3]
METHOXYUNDECYLPHOSPHINIC ACID DMY0O7X Discovery agent N.A. Investigative [3]
Daio-Orengedokuto (DOT) DM3M652 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pancreatic triacylglycerol lipase (PNLIP) TTXMY0J LIPP_HUMAN Inhibitor [1]
Rhodopsin (RHO) TTH0KSX OPSD_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
3 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Pfizer. Product Development Pipeline. March 31 2009.
6 Clinical pipeline report, company report or official report of Digestive Care.
7 Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
8 Clinical pipeline report, company report or official report of AzurRx.
9 US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor.
10 Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.